CDK4 and breast carcinoma: Since this trial participants are by eligibility criteria breast cancer patients with an indication to CDK4/6 inhibitors in clinical practice, the comparison between the rate of accrual pre‐ and post‐March 2020 may be intended as a proxy of this specific treatment assignment in course of lockdown.